Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Assets Average (2021 - 2025)

Historic Assets Average for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $48.1 million.

  • Lyra Therapeutics' Assets Average fell 4445.42% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 4445.42%. This contributed to the annual value of $104.5 million for FY2024, which is 1727.14% down from last year.
  • As of Q3 2025, Lyra Therapeutics' Assets Average stood at $48.1 million, which was down 4445.42% from $54.4 million recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Assets Average high stood at $142.1 million for Q1 2024, and its period low was $48.1 million during Q3 2025.
  • In the last 5 years, Lyra Therapeutics' Assets Average had a median value of $87.7 million in 2022 and averaged $90.9 million.
  • Its Assets Average has fluctuated over the past 5 years, first soared by 9942.47% in 2023, then tumbled by 5682.85% in 2025.
  • Lyra Therapeutics' Assets Average (Quarter) stood at $61.3 million in 2021, then skyrocketed by 87.09% to $114.7 million in 2022, then increased by 14.71% to $131.6 million in 2023, then plummeted by 44.86% to $72.6 million in 2024, then crashed by 33.65% to $48.1 million in 2025.
  • Its last three reported values are $48.1 million in Q3 2025, $54.4 million for Q2 2025, and $61.3 million during Q1 2025.